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Summary
Background The physical appearance of psoriasis can be cosmetically disfiguring,
resulting in a substantial social burden for patients. An important aspect of this
burden is the experience of stigmatization. While stigmatization is known to be
disabling and stressful for patients, little is known about its correlates, and effec-
tive interventions are lacking.
Objectives To examine predictor variables for perceived stigmatization in psoriasis.
Methods Questionnaires were administered to 514 patients with psoriasis in a
cross-sectional study. Zero-order correlation and multiple-regression analyses
were conducted including sociodemographic, disease-related, personality, illness
cognitions and social support predictor variables.
Results Stigmatization was experienced by 73% of patients to some degree, and
correlated with all five categories of predictor variables. In multiple-regression
analyses, stigmatization was associated with higher impact on daily life; lower
education; higher disease visibility, severity and duration; higher levels of social
inhibition; having a type D personality; and not having a partner.
Conclusions The results indicate that perceived stigmatization is common in psoriasis,
and can be predicted by sociodemographic, disease-related and personality vari-
ables. These predictor variables provide indications of which patients are especially
vulnerable regarding perceived stigmatization, which might be used in treatment.
What’s already known about this topic?
• Perceived stigmatization is common and distressing in patients with psoriasis.
• Some of its predictors have been examined in small samples.
What does this study add?
• This large study of 514 patients with psoriasis examined a combination of potential
predictor variables, both previously examined and never before studied.
• Sociodemographic, disease-related and previously unstudied type D personality
variables were found to be predictive of perceived stigmatization.
What are the clinical implications of this work?
• These results provide an understanding of which patients may be especially vulner-
able to stigmatization-related problems, which may warrant special attention dur-
ing treatment.
© 2016 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017) 176, pp687–694 687
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
It has long been theorized that humans have a fundamental
need to be accepted by others and included in social interac-
tions.1 Social relationships are important for health and well-
being, and social rejection can lead to physical, behavioural
and emotional problems.1 Social rejection is central to the
experience of stigmatization, which can be defined as an
awareness of social disapproval, discrediting or devaluation
based on an attribute or physical mark.2,3
In psoriasis, a chronic skin condition characterized by red
plaques on the skin,4 the experience of stigmatization is com-
monly mentioned as one of its more troubling characteris-
tics.5–9 Patients often experience felt or perceived stigma,
referring to the negative attitudes and responses that they per-
ceive to be present in society and the sense of shame and fear
of being discriminated against because of being ‘flawed’ due
to their illness.10,11 Actual experiences of stigmatization (i.e.
enacted stigma) are also reported, for instance reactions of dis-
gust or aversion, negative comments or avoidance of con-
tact.7,9 Stigmatization contributes considerably to disability,
depression and reduced quality of life in psoriasis,12–14 and
can be considered a stressor. As distress can be a trigger for
psoriasis exacerbation, this can become a vicious self-perpetu-
ating cycle.15–17
Despite these detrimental consequences, relatively few stud-
ies have studied interventions targeting stigmatization-related
problems, and thus far no compelling evidence has been
found for any type of intervention.18,19 Firstly, it is important
to recognize that stigmatization is a societal problem, and
therefore societal educational interventions including contact
between patients and the general population are called for to
alter the public view.20 Furthermore, interventions with a
more inter- and intrapersonal focus are needed to improve
patients’ ability to cope with perceived stigmatization. In order
to aid intervention development, a broad understanding of
associated risk factors is needed, to be able to identify risk
populations and focus points for interventions.
The literature suggests several potential sociodemographic
predictors of perceived stigmatization in psoriasis, such as
lower age,7 being female5 and lower education.7
Secondly, disease-related variables such as higher disease
severity, longer disease duration, greater cosmetic involvement
and greater impact of the condition on daily life may be rele-
vant.7–9,13,21,22 General ways in which patients deal with a
chronic condition, such as heightened helplessness regarding
the disease and its consequences, and lower disease acceptance
have also been found to be predictive.7 Additionally, social
support and a large social network may serve a protective
function against experiences of stigmatization.7
While several studies have examined the above-mentioned
variables as predictors, the role of personality has hardly
been studied.7,9 A possibly relevant personality construct is
type D, which is defined as a tendency to inhibit the expres-
sion of emotions or behaviour to avoid negative reactions of
others (social inhibition; SI), in combination with the stable
tendency to experience negative affect (negative affectivity;
NA).23 Type D personality has been associated with increased
risk of cardiovascular morbidity and mortality24 and impaired
health behaviour,25 which are both frequently reported in
psoriasis.26,27 The two main features – SI and NA – may
both increase the impact of perceived stigmatization. Being
socially inhibited implies being sensitive to negative reactions
of others, which may cause stigmatization experiences to be
especially detrimental. Additionally, having a stable tendency
to experience negative affect may worsen psychological dis-
tress, which in turn may increase disease severity and resul-
tantly visibility,15–17 and thereby vulnerability to
stigmatization experiences. Furthermore, individuals with
high levels of NA may be more likely to perceive social
interactions as negative, due to the associated cognitive bias
to negative information.28 The specific combination of
heightened SI and NA, type D, has been related mainly to
adverse outcomes in cardiovascular patients,24,29–31 but also
to poorer physical, psychological and social functioning in
other healthy and patient samples,32,33 including two studies
in psoriasis.34,35
This study aims to examine the relative contributions of a
broad range of concepts, including previously unstudied vari-
ables such as type D personality, to perceived stigmatization in
a large sample of patients with psoriasis. It was hypothesized
that perceived stigmatization would be related to the sociode-
mographic variables age, educational level and being single;
the disease-related variables severity, duration, visibility and
impact; type D personality; the illness cognitions acceptance
and helplessness; and social support. This broad approach may
provide indications for screening and interventions for reduc-
ing stigmatization-related problems.
Patients and methods
Participants
Patients with psoriasis were recruited from one academic and
three nonacademic hospitals, and the Dutch Psoriasis Associa-
tion. Inclusion criteria were a minimum age of 18 years and a
dermatologist-confirmed psoriasis diagnosis. Exclusion criteria
were illiteracy, pregnancy and severe physical and mental
comorbid conditions. This study made use of questionnaires
that were administered between 2010 and 2013 to determine
participant eligibility for a study on the effectiveness of inter-
net-based cognitive behavioural treatment for psoriasis.36 Parts
of these data have been used in a previous paper.37 All ques-
tionnaires were assessed prior to the intervention. The study
was approved by the regional medical ethics committee and
carried out in accordance with the Declaration of Helsinki.38
All participants provided informed consent.
Measures
Perceived stigmatization was measured with a six-item sub-
scale of the Impact of Chronic Skin Disease on Daily Life ques-
tionnaire (ISDL;39 Cronbach’s a in this study = 088). This
assesses to what extent the patient feels stigmatized as a result
© 2016 The Authors. British Journal of Dermatology
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of the skin condition. Items are assessed on a four-point Likert
scale, with higher scores reflecting higher levels of perceived
stigmatization (theoretical range 6–24). Example items are
‘others feel uncomfortable touching me due to my skin dis-
ease’ and ‘other people sometimes make annoying comments
about my skin disease’.
Measures used for assessment of predictor variables
Sociodemographic variables
Sociodemographic variables were assessed with a general
checklist that assessed patients’ sex, age, educational level and
marital status. Educational level was categorized into primary
(i.e. lower education, elementary school), secondary (i.e. mid-
dle school and high school, including vocational training) and
tertiary (i.e. higher professional education and university-level
education).
Disease-related variables
Self-assessed disease severity was measured with the Self-
Administered Psoriasis Area and Severity Index (SAPASI,40,41
theoretical range 0–72). Self-assessed disease visibility was
measured with a four-item ISDL subscale39 asking about the
extent of involvement of the face, scalp, neck and hands (the-
oretical range 4–16). Disease duration was assessed by asking
how old the patient was when diagnosed, and subtracting this
number from their current age (range 0–64 years). Impact of
the disease on daily life was assessed with a 10-item ISDL sub-
scale39 assessing the extent to which the skin condition affects
daily-life activities (theoretical range 10–40, a = 089).
Personality
The Type D Scale-1423 was used to assess type D personality.
It consists of two seven-item subscales: SI (a = 088, example
item: ‘I often feel inhibited in social interactions’, theoretical
range 0–28) and NA (a = 089, example item: ‘I often feel
unhappy’, theoretical range 0–28). A cut-off score of ≥ 10 on
both scales is used to classify type D personality. Using these
cut-off scores, one in four participants in this study (251%)
had a type D personality. As previous studies indicate that type
D is best represented as a continuous variable,42,43 the interac-
tion term between the NA and SI subscales was used as a mea-
sure of type D.
Illness cognitions
The Illness Cognition Questionnaire44 was used to measure
two illness cognitions: acceptance, assessing the extent of pos-
itive adaptation to chronic illness with emphasis on decreasing
its negative aspects (six items, a = 088, theoretical range 6–
24) and helplessness, assessing the extent to which patients
concentrate on aversive aspects of the disease (six items,
a = 088, theoretical range 6–24).
Social support
Social support was assessed with a five-item ISDL subscale,39
assessing the qualitative aspect of social support (a = 086,
theoretical range 5–20), and the quantitative aspect, asking
patients about the actual size of their social network (range 0–
25). This score was categorized according to norm groups.39
Statistical analysis
All variables were checked for outliers, normality and normal
distribution of residuals, and logarithmic transformations were
successfully applied in case of non-normal distribution of vari-
ables (i.e. perceived stigmatization, helplessness and disease
severity). Winsorizing was applied in outlying SAPASI scores
prior to log transformation, limiting the influence of extreme
values. Zero-order correlations between perceived stigmatiza-
tion and predictor variables were examined by Pearson correla-
tion coefficients for continuous variables, and t-tests and ANOVA
for categorical variables. Zero-order correlations were inter-
preted as small (r = 010–029), moderate (r = 030–049) or
large (r ≥ 050).45 Only study variables showing significant
zero-order correlations with perceived stigmatization were
entered in regression analyses. To study the relative contribution
of five categories of variables (sociodemographic, disease-
related, personality, illness cognitions and social support), each
category was entered in a consecutive step with perceived
stigmatization as the dependent variable. Only statistically sig-
nificant individual predictor variables (P < 005) were retained
in further models. For type D personality, the main effects of
mean-centred NA and SI were first examined, and in a second
block their interaction term was added. All regression analyses
were conducted with SPSS 21.0 (IBM, Armonk, NY, U.S.A.) on
a dataset without missing values (n = 433).
Results
Sample characteristics
The sociodemographic characteristics of the study sample
(n = 514) and means and SDs of the study variables can be
found in Tables 1 and 2. Disease severity was generally mild
to moderate, with 67% of patients having severe psoriasis
(SAPASI > 10).46 The mean values of perceived stigmatization,
impact on daily life, social support and illness cognitions were
similar to those found in previous research in psoriasis,39 and
scores on type D personality were comparable with those
found in the general population.33,47
Perceived stigmatization
Seventy-three per cent of our sample perceived at least some
stigmatization, as indicated by a positive score on at least one
of the six items, as reported in previous studies.7,8 The feeling
of being stared at was reported most often (in 619% of
patients), followed by other people thinking their condition
© 2016 The Authors. British Journal of Dermatology
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was contagious (449%), finding them unattractive because of
their skin condition (381%), avoiding touching them
(323%) and making negative comments (277%).
Individual associations with perceived stigmatization
Zero-order correlations of the study variables are reported in
Table 3. Higher perceived stigmatization showed a large cor-
relation with a greater impact of the skin condition on daily
life; moderate correlations with higher disease severity, help-
lessness, NA and lower levels of acceptance; and small correla-
tions with lower age, longer disease duration, greater
visibility, higher levels of SI, and less perceived social support.
Furthermore, higher perceived stigmatization scores were
associated with a smaller social network (P = 0001), not hav-
ing a partner (P < 0001) and lower educational level
(P = 001), but not with sex (P = 100).
Relative impact on perceived stigmatization
Table 4 presents the results of multiple-regression analyses
that were performed to examine the relative impact of predic-
tors on perceived stigmatization.
In block 1, sociodemographic variables explained 119% of
the variance in perceived stigmatization, with lower age,
lower education and being single being predictive of higher
levels of perceived stigmatization. In block 2, adding the dis-
ease-related variables explained a total of 483% of the vari-
ance, with greater disease severity and visibility, longer
disease duration and higher disease impact predicting more
perceived stigmatization. In block 3, adding the personality
variables resulted in a total of 497% explained variance, with
the main effect of SI (but not NA) and the type D interaction
effect being predictive of perceived stigmatization. Patients
scoring high on both SI and NA, indicating a type D personal-
ity, had higher levels of perceived stigmatization (Fig. 1). In
blocks 4 and 5, illness cognitions of helplessness and accep-
tance, and perceived and actual social support did not signifi-
cantly add to the model.
The final model, including only the significant predictors,
explained a total of 497% of the variance in perceived stigma-
tization (Table 5). The predictors, from highest to lowest
standardized regression coefficients, were higher disease
impact, lower age, lower education and greater disease visibil-
ity, longer disease duration, higher disease severity and higher
levels of SI, having a type D personality, and being single. A
model excluding multivariate outliers (n = 16; critical Maha-
lanobis distance value = 3291, degrees of freedom = 12,
P = 0001) yielded similar results, with the exception of two
predictors that became marginally significant (type D personal-
ity, P = 008) or nonsignificant (marital status, P = 011).
Discussion
This study examined perceived stigmatization and its potential
sociodemographic, disease-related and psychosocial predictors
in a large sample of patients with psoriasis. The vast majority
of our sample experienced perceived stigmatization to some
degree, corresponding with previous studies.7,8 Higher levels
of perceived stigmatization were found to be correlated with
sociodemographic and disease-related variables, personality,
illness cognitions and social support. Perceived stigmatization
was found to be particularly predicted by disease impact, as
well as by lower age, lower education, greater disease severity
and visibility, longer disease duration, higher levels of SI, hav-
ing a type D personality and being single.
Greater severity and visibility and longer disease duration
were predictive of perceived stigmatization, underlining the
importance of early dermatological treatment; patients whose
psoriasis is not adequately controlled may be more affected by
stigmatization. However, the impact of the condition was a
much stronger predictor, corresponding with the notion that
the subjective experience of impact is generally more impor-
tant than disease severity.48,49 In contrast with an earlier
Table 1 Sociodemographic characteristics of the study sample
(n = 514)
Patient characteristics Descriptives
Age (years), mean  SD; range 522  130; 18–84
Sex
Male 286 (556)
Female 228 (444)
Marital status
Unmarried 62 (121)
Married/living together 410 (798)
Divorced 24 (47)
Widowed 18 (35)
Educational status
Primary 16 (31)
Secondary 306 (595)
Tertiary 190 (370)
Missing 2 (04)
Values are n (%) unless stated otherwise.
Table 2 Means and SDs of study variables (n = 514)
Characteristic Mean  SD Range
Perceived stigmatization 902  348 6–24
Disease related
Disease severitya 509  402 0–33
Disease visibility 185  057 10–35
Disease duration (years)b 1572  1475 0–62
Impact on daily life 1606  606 10–40
Type D, n (%) 129 (251)
Negative affectivity 845  602 0–26
Social inhibition 913  601 0–27
Illness cognitions
Helplessness 938  374 6–24
Acceptance 1719  446 6–24
Social support
Perceived support 1580  360 5–20
Actual support 812  533 0–25
an = 489; bn = 498.
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study,7 the impact of the condition was also a stronger predic-
tor than the illness cognition of helplessness. The relative and
different contribution of both variables may be explained by
the high correlation between these variables in the current
study and in previous research.48 It seems likely that patients
with psoriasis who are prone to feelings of helplessness
regarding the disease may also experience a larger impact of
psoriasis and magnify negative reactions of others.
Type D personality and its subcomponent SI were found to
be significant predictors of perceived stigmatization. The fear
of disapproval that leads individuals to inhibit emotions or
behaviour in SI23 may explain its relation to perceived
Table 3 Zero-order correlation matrix of continuous study variables
Variable 1 2 3 4 5 6 7 8 9 10 11
1 Stigmatization –
2 Age 028*** –
3 Disease
severity
034*** 014** –
4 Disease
visibility
026*** 012** 029*** –
5 Disease
duration
013** 022*** 011* 003 –
6 Disease impact 061*** 017*** 032*** 026*** 011* –
7 Type D: NA 030*** 023*** 020*** 012* 005 036*** –
8 Type D: SI 022*** 011* 005 007 003 017*** 041*** –
9 Helplessness 049*** 009# 028*** 019*** 010* 067*** 039*** 017*** –
10 Acceptance 034*** 010* 019*** 023*** 010* 048*** 042*** 020*** 052*** –
11 Perceived
support
016*** 002 002 000 000 018*** 036*** 027*** 017*** 026*** –
NA, negative affectivity; SI, social inhibition. *P < 005, **P < 001, ***P < 0001, #P < 010.
Table 4 Predictors of stigmatization: multiple-regression analyses
Predictors
Standardized regression coefficients (b)
Block 1 Block 2 Block 3 Block 4 Block 5
Sociodemographic
Age 027*** 019*** 019*** 019*** 018***
Education (primary)a 006 003 003 003 002
Education (secondary)a 015** 012*** 012** 011** 011**
Married/with partnerb 013** 007* 007# 007# 006
Disease related
Disease severity 010** 010** 010* 011**
Disease visibility 012** 012** 012** 012**
Disease duration 011** 011** 011** 009*
Impact on daily life 051*** 050*** 046*** 050***
Personality
Negative affectivity (NA) 000 001 002
Social inhibition (SI) 010** 010* 009*
Type D personality (interaction NA*SI) 008* 008* 007*
Illness cognitions
Helplessness 005
Acceptance 001
Social support
Perceived support 003
Actual support (1–4)c 015
Actual support (5–14)c 017
Actual support (15–25)c 013
F-change 1678*** 7616*** 431** 044 063
R2 012 048 050 050 050
aReference group = tertiary education. bReference group = no partner. cNumber of friends, reference group = no friends. *P < 005,
**P < 001, ***P < 0001, #P < 010.
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stigmatization; socially inhibited individuals may be more sen-
sitive to the reactions of others and may therefore perceive
themselves to be stigmatized more readily. Not only SI in
itself, but also the combination of higher levels of SI and NA
(type D personality) was a significant predictor of perceived
stigmatization. This corresponds with studies suggesting that
type D is associated with social impairments.50,51 These results
extend preliminary evidence indicating that type D may be a
risk factor for worse outcomes in psoriasis,34,35 by showing
for the first time that it is associated with increased perceived
stigmatization. However, these results should be replicated in
further research, as the effect of type D became only margin-
ally significant when excluding multivariate outliers. In the
current study, NA was not a significant predictor of perceived
stigmatization. It seems that, while the shared variance with
NA can also be explained by other variables, SI contains more
unique information relevant for perceived stigmatization.
Regarding sociodemographic variables, the significant pre-
dictors lower age, lower educational level and being single
were in line with previous research indicating that the nega-
tive psychosocial influence of psoriasis is particularly strong in
younger patients.7,52
To develop a comprehensive model of factors influencing
perceived stigmatization, both potential risk factors (e.g. social
fears and inhibition) and protective factors (e.g. social sup-
port) need to be taken into account. While the current study
provides evidence for the former, results of the latter (social
support) were inconsistent with previous research,7 possibly
due to the inclusion of predictor variables not previously stud-
ied. Furthermore, while the current study examined self-per-
ceived support, a more objective measure may lead to
different results. Nonetheless, the current results suggest that
it is not so much the experienced social support that plays a
significant role in perceived stigmatization, but more the
extent to which patients may experience social anxiety and
want to avoid negative reactions, as captured in SI. Future
research should explore further the role of protective factors
in perceived stigmatization.
Strengths of the current study include the large sample size,
simultaneous assessment of relevant variables to control for
shared variance, including personality variables never before
studied, and inclusion of patients from a variety of settings.
Limitations include the cross-sectional design, precluding con-
clusions about cause and effect, and the relatively mild disease
severity of our sample, which may limit generalizability. In
addition, self-reported measures were used to assess disease
severity. However, self-assessed Psoriasis Area and Severity
Index (PASI) scores correlate reasonably well with clinician-
assessed PASI scores,40,53 and modest relationships with
stigmatization have also been found in studies using clinician-
assessed PASI.54,55 Lastly, some predictor variables showed
high intercorrelations, but none of them was above the multi-
collinearity cut-off point of 080.56
In conclusion, perceived stigmatization was found to be
common in patients with psoriasis and was predicted by
specific sociodemographic, disease-related and personality
variables. This provides several possible focus points for indi-
vidual screening and interventions, in addition to the societal
interventions that are needed to target the overarching prob-
lem. Firstly, the predictors found in this study provide clini-
cians with an understanding of which patients may be
especially vulnerable to stigmatization-related problems, which
may warrant special attention during consultations. Type D
and especially its SI component may be screened for, when
Fig 1. Interaction effect of negative affectivity (NA) and social
inhibition (SI) on perceived stigmatization. Predicted values of
perceived stigmatization are displayed for high and low levels of NA
and SI (i.e. 1 SD above and below the mean). For all other variables
included in the model, mean scores were used to calculate the
regression outcome. In this figure, the degree of SI was not associated
with perceived stigmatization when patients had low NA. For patients
with high NA, specifically the combination with high SI, indicating a
type D personality, this was related to higher levels of perceived
stigmatization.
Table 5 Predictors of stigmatization: final model
Predictors b B SE
Sociodemographic
Age 019*** 000*** 000
Married/with partnera 007# 002# 001
Education (primary)b 004 003 003
Education (secondary)b 012** 003** 001
Disease related
Disease severity 010* 002* 001
Disease visibility 012** 003** 001
Disease duration 011** 000** 000
Impact on daily life 050*** 001*** 000
Personality
Negative affectivity 000 000 001
Social inhibition 010** 001** 000
Type D 008* 001* 000
F-change 3780***
R2 050
b, standardized coefficients; B, unstandardized coefficients; SE,
standard error of B. aReference group = no partner. bReference
group = tertiary education. *P < 005, **P < 001,
***P < 0001, #P < 010
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further evidence confirms our preliminary results indicating
that individuals with this personality subtype are especially
vulnerable to stigmatization-related problems. Stigmatization-
related problems may be screened for using validated instru-
ments,39 followed by targeted interventions that may focus on
the impact of the condition on daily life, considering that this
was the largest predictor. Cognitive behavioural treatment,
including social skills training, seems promising as an inter-
vention framework. Previous research indicates that it can
decrease perceived stigmatization in skin conditions,57
improve psychological and disease-related outcomes in psoria-
sis,58,59 and decrease helplessness, which shows high correla-
tions with disease impact.60–62 In order to target the SI aspect
of type D personality, social skills training and evidence-based
interventions for social fears, such as cognitive behavioural
therapy and/or exposure therapy, may be an additional treat-
ment approach.63,64
The current study provides a framework of characteristics
of patients who are at greater risk to perceive stigmatiza-
tion, which has been shown to have detrimental psycholog-
ical consequences in psoriasis. Future research should
expand upon these findings in order to examine interplays
between predictors in prospective studies. Further develop-
ment of screening and intervention procedures is needed in
order to facilitate implementation of tailored evidence-based
treatment to reduce the psychosocial burden of chronic skin
conditions.
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